Table 3.
The effects of pivaloylacylation-7ADCA on CHL cell chromosome aberration
| Dose (μg/ml) | -S9 | +S9 | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| 24 h | 48 h | 24 h | 48 h | |||||
|
|
|
|
|
|||||
| Number of distortion | Frequency of aberrant chromosomes % | Number of distortion | Frequency of aberrant chromosomes % | Number of distortion | Frequency of aberrant chromosomes % | Number of distortion | Frequency of aberrant chromosomes % | |
| 1250 | 4 | 2 | 4 | 3 | 4 | 2 | 5 | 2.5 |
| 2500 | 3 | 1.5 | 3 | 1.5 | 6 | 3 | 4 | 2 |
| 5000 | 7 | 3.5 | 6 | 2.0 | 3 | 1.5 | 5 | 2.5 |
| DMSO | 2 | 1b | 4 | 2b | 3 | 1.5b | 3 | 1.5b |
| Positive control | 61 | 30.5a | 59 | 29.5a | 65 | 32.5a | 57 | 28.5a |
In vitro mammalian chromosome aberration assay was further used to evaluate the genotoxicity of Pivaloylacylation-7ADCA on chromosome level. Cells were exposed to a range of dosages of pivaloylacylation-7ADCA (1250, 2500 and 5000 μg/ml). Cells treated with DMSO alone were employed as the solvent control. In the absence of S9 mixture, cells treated by 0.1 μg/ml of mitomycin C (MMC) were used as positive control; while in the presence of S9, cells treated by 20 μg/ml of cyclophosphamide (CP) was employed as the positive control.
denotes a significant difference in the frequency of aberrant chromosomes (%) compared to the DMSO control group.
Statistical significance was set as P<0.05.